Patent · US Active

(S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor

US10961236B2 · kind B2 · utility

0Cited by

0References

6Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Matthew Perry · Coalville, GB
Christian Tyrchan · Mölndal, SE
Konstantinos KARABELAS · Mölndal, SE
Antonios Nikitidis · Lund, SE
Mickael Mogemark · Mölndal, SE
Jens PETERSEN · Mölndal, SE
Peter BOLD · Mölndal, SE
Ulf BORJESSON · Mölndal, SE

Key dates

Filing date	Sep 21, 2017
Grant date	Mar 30, 2021
Priority date	—
Expiry date	Jan 27, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Disclosed herein is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one of the following structure: and/or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof, which inhibit phosphatidylinositol 3-kinase (PI3K) activity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.